Resmed reports revenue growth for fiscal year 2026 fourth quarter
Medical device manufacturer Resmed posted $1.5 billion in revenue for its final fiscal quarter, marking a 9% year-over-year increase.
Resmed Inc. announced its financial results for the quarter ended June 30, 2026, recording $1.5 billion in revenue. This represents a 9% growth compared to the same period in 2025, or 8% on a constant currency basis. For the full fiscal year 2026, the company generated $5.7 billion in revenue, reflecting a 10% annual increase.
GAAP diluted earnings per share for the quarter rose 2% to $2.64, while non-GAAP diluted earnings per share increased by 16% to $2.95. The company’s operating cash flow for the year reached $1.8 billion, with free cash flow totaling $1.6 billion.
Operationally, the company is adjusting its portfolio with a planned sale of its MatrixCare business and the recent acquisition of Noctrix Health, which provides wearable therapeutics for Restless Leg Syndrome. CEO Mick Farrell stated that the company will continue to leverage global scale and digital capabilities to improve patient outcomes and operational efficiency.
Resmed returned over $1 billion to shareholders during the 2026 fiscal year. Looking toward fiscal year 2027, the company has pledged to return more than $1.85 billion through dividends and share repurchases, alongside a 10% increase in its quarterly dividend.